Use of pioglitazone in the treatment of diabetes: Effect on cardiovascular risk

24Citations
Citations of this article
25Readers
Mendeley users who have this article in their library.

Abstract

Pioglitazone and other thiazolidinediones (TZDs) initially showed great promise as unique receptor-mediated oral therapy for type 2 diabetes, but a host of serious side effects, primarily cardiovascular, have limited their utility. It is crucial at this point to perform a risk-benefit analysis to determine what role pioglitazone should play in our current treatment of type 2 diabetes and where the future of this class of drugs is headed. This review provides a comprehensive overview of the present literature. Clinical data currently available indicate that pioglitazone is an effective and generally well-tolerated treatment option for use in patients with type 2 diabetes. Pioglitazone can still reduce adverse cardiovascular risk. © 2013 Zou and Hu.

Cite

CITATION STYLE

APA

Zou, C., & Hu, H. (2013). Use of pioglitazone in the treatment of diabetes: Effect on cardiovascular risk. Vascular Health and Risk Management. https://doi.org/10.2147/VHRM.S34421

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free